Search
Thenyldiamine
go.drugbank.com/drugs/DB16022ApprovedWithdrawnMixtures: Neo Synephrine Nasal Spray, Neo-synephrine Nasal SprayADX-10061
go.drugbank.com/drugs/DB05419ExperimentalIt is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated … for the treatment of advanced non-small cell lung cancer (NSCLC).
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalDeveloped by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.
Tenamfetamine
go.drugbank.com/drugs/DB01509IllicitInvestigationalIt is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEnrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use. … Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14385ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14390ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14393ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB14394ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.